Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia

    loading  Checking for direct PDF access through Ovid

Abstract

The best management strategy for HIV patients who fail to respond to first-line therapy for Pneumocystis jirovecii pneumonia is currently unclear. We identified all patients who were treated with trimetrexate and folinic acid who failed 7 or more days of cotrimoxazole, clindamycin–primaquine or dapsone–trimethoprim between 1996 and 2006. Trimetrexate was tolerated in 100% of cases with no treatment termination secondary to adverse drug reactions. Despite severe disease, 71% of patients were alive after 12 weeks.

Related Topics

    loading  Loading Related Articles